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Background: Although rotavirus vaccines have been licensed in Spain for over 8 years, they are not funded by its
public health systems. The analysis of their effectiveness in the Valencia Region could better inform decisions about
potential inclusion in the official immunization schedule. Our aim was to assess the effectiveness of Rotarix® (RV1)
and RotaTeq® (RV5) against rotavirus hospitalizations.
Methods: We conducted a retrospective cohort study using the region’s health care databases, among resident
children aged <3 years covered by the National Health System, during January 2007-June 2012. We compared two
cohorts of vaccinated children: the first included children who received at least one dose of a rotavirus vaccine, and
the second included children who were not vaccinated with rotavirus vaccines but received at least one dose of a
pneumococcal vaccine, another licensed but non-funded vaccine. The main outcome was rotavirus hospitalization,
either laboratory-confirmed (confirmed) or codified as rotavirus (probable). Rotavirus vaccine effectiveness (RVE) by
vaccine brand was assessed using Cox proportional hazards models.
Results: The study included 78,281 rotavirus and 96,643 pneumococcal vaccinees. Adjusted RVE against probable or
confirmed rotavirus hospitalizations was 86% (95% CI: 78-91%) and 88% (95% CI: 81-92%) for a complete series of
RV1 and RV5 respectively.
Conclusions: Both rotavirus vaccines were over 85% effective against rotavirus hospitalization among young children.
The high effectiveness shown argues in favor of their inclusion in the official schedule. Additional information on
rotavirus vaccine safety, duration of protection, and benefit-risk will also be needed to inform such deliberations.
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Rotavirus is the leading cause of severe pediatric gastro-
enteritis: 39% (29%-45%) of hospitalized diarrhea cases
worldwide during 2000–2004 were attributable to rotavirus
[1]. In the Valencia Region, rotavirus is responsible for 53%
of all gastroenteritis hospitalizations among children
aged <5 years [2]. Younger children have a significantly
higher risk of a primary infection leading to severe diar-
rhea, defined as diarrhea requiring hospitalization. Most
serious episodes occur among children aged 3–35 months.* Correspondence: diez_jav@gva.es
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unless otherwise stated.Children who suffer natural rotavirus infection develop
some immunity to disease, decreasing the severity of sub-
sequent infections and increasing the protective effect
following each infection. Natural infection may provide
protection against multiple serotypes since the antibody re-
sponse to natural infection appears to be heterotypic [3,4].
Two oral live-attenuated rotavirus vaccines are currently
licensed: a monovalent human vaccine (RV1), (Rotarix®;
GlaxoSmithKline Biologicals, Rixensart, Belgium), indicated
as a two-dose series in infants between the ages of 6–12
and 24 weeks [5], and a pentavalent bovine-human reassor-
tant vaccine (RV5), (RotaTeq®; Merck & Co., Inc., West
Point, PA, USA), indicated as a three-dose series starting at
6–12 weeks and ending ≤32 weeks of age [6]. Both vaccinestral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vaccine [7,8], and high direct effectiveness in preventing
rotavirus cases and hospitalizations [9-13]. Herd immunity
has been suggested by studies from countries that intro-
duced universal rotavirus vaccination [13-15].
RV1 and RV5 have been available in Spain since August
2006 and January 2007, respectively. Although institutions
such as the World Health Organization, the Centers for
Disease Control and Prevention, and the Pediatric Spanish
Society, recommend the inclusion of rotavirus vaccination
in national immunization programmes [4,16-18], rotavirus
vaccines are not funded by the Spanish National Health
System (NHS). Due to the incidental finding of circovirus
DNA contamination in both vaccines, the Spanish Medi-
cines Agency suspended RV5 distribution during June-
November 2010, and RV1 distribution since March 2010
[19]. As of this publication, RV1 distribution remains sus-
pended in Spain.
Our objective was to assess rotavirus vaccine effect-
iveness (VE), in complete and incomplete schedules, to
prevent severe rotavirus gastroenteritis among children
aged <3 years in the Valencia Region using electronic
health care databases. Since rotavirus vaccines in Spain,
a country with universal health coverage, are licensed
but not funded, results of this study could better inform
decisions regarding the potential inclusion of these vac-
cines in the official immunization schedule.
Methods
Retrospective cohort study of Valencia Region’s children
covered by the Spanish Health Care System performed
using the region’s health care databases during 1st January
2007- 30th June 2012.
Study setting and data sources
The Valencia Region has a population of approximately
5,000,000 inhabitants and an annual birth cohort of around
48,000 infants. Almost all the population (98.3%) is covered
by the health system [20], which includes 24 pediatric hos-
pitals. All health care users have a unique identification
number that allows linking all health care databases and
all medical records. The regional population-based admin-
istrative database, SIP, collects and updates demographic
data, health services assignment, and use of the NHS, for
both residents and non-residents.
Hospitalized cases were obtained from CMBD, the
Spanish hospital discharge database [21]. In CMBD, diagno-
ses and procedures are collected as an assessment of med-
ical activity and coded by trained personnel. The coding
system used is the International Classification of Diseases
9th Revision, Clinical Modification (ICD-9-CM). Using
CMBD is compulsory for all public hospitals. The regional
microbiological surveillance network database, RedMIVA,
provided rotavirus detection results; this database is linkedto all Valencia’s public microbiological laboratories daily
[22]. Vaccination status was obtained from SIV, the re-
gional vaccine information system. Funded and non-
funded vaccines administered in all public and some
private health centers are recorded on SIV [23]. Registra-
tion procedures are the same regardless of whether vac-
cines are included in the official immunization schedule.
Study population
The study included all children aged <36 months born
since 1st January 2007 until the end of the study period,
affiliated to the NHS at six weeks of age or earlier, residents
in the Valencia Region for at least four weeks, and registered
in SIV as vaccinated with at least one dose of rotavirus
and/or pneumococcal conjugate vaccine (PCV). Children
who received at least one dose of rotavirus vaccine
(having, or not, received PCV) were included in the
rotavirus-vaccinated cohort, and children who received at
least one dose of PCV but no rotavirus vaccine were
included in the comparison cohort. As rotavirus vac-
cines, PCVs are licensed but not included in the official
immunization schedule; they are also administered to
infants from six weeks of age onwards.
Children were excluded from the study if they were vac-
cinated before six weeks of age, after one year of age, with
less than three weeks elapsed between administrations
of subsequent vaccine doses, with more than one vaccine
brand, with unknown vaccine brand, with more than two
doses of RV1, or with more than three doses of RV5.
The observation period began on birthdate and ended
on: (1) the date of exit in SIP (regardless of the reason),
(2) the date of the first rotavirus positive result, (3) the first
rotavirus hospitalization (ICD-9-CM code 008.61 in any
diagnosis position), (4) the end of the study period, or (5)
the date prior to reaching 36 months of age, whichever
occurred earlier.
Case definition
Our outcomes were: (a) confirmed hospitalized rotavirus
cases, defined as first hospitalization with a discharge
diagnosis of intestinal infectious disease (ICD-9-CM codes
001–009) in any diagnosis position, plus a laboratory con-
firmed rotavirus result associated with the admission; and
(b) probable hospitalized rotavirus cases, defined as first
hospitalization with a discharge diagnosis of enteritis
due to rotavirus (ICD-9-CM code 008.61) in any diagnosis
position.
A laboratory confirmed rotavirus test was considered
associated to the admission if the result was available within
five days prior to admission and 15 days after discharge.
Stool samples were assayed using techniques made avail-
able by each hospital. The decision to perform a stool test
was not systematic and depended on each health depart-
ment and pediatrician.
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Vaccination status was assessed as a time-varying expos-
ure. Eligible children were considered as vaccinated with
a dose of rotavirus vaccine when at least 14 days [7] had
elapsed since each dose administration. The following
categories were used:
1) Fully vaccinated (three doses of RV5 or two doses of
RV1);
2) Partially vaccinated two doses (two doses of RV5);
3) Partially vaccinated one dose (one dose of RV5 or RV1);
4) Unvaccinated (absence of record for rotavirus
vaccination in SIV);
If one or more of the vaccine doses registered as ad-
ministered did not indicate vaccine brand, the brand as-
sumed for all doses was the one specifically mentioned for
the remaining doses.
Statistical analysis
Proportions in distribution by gender, residence status
(as registered in SIP), year of birth, having health coverage
within the public system at the time of data extraction,
having received any vaccination by a private provider, and
performance of a rotavirus laboratory test were compared
using chi-square and Fisher’s exact tests.
Age at dose administration and intervals between doses
were described for rotavirus vaccinees using proportions
and medians.
Rotavirus VE was calculated as (1-hazard ratio) x 100%.
Cox proportional hazard models with time-varying co-
variates were used for estimating the hazard of rotavirus
hospitalization for the study groups. The model was ad-
justed for gender, having received any vaccination by a
private provider, and zip code (random effects). Rotavirus
seasonality (December-April) [24], and year of birth did
not satisfy the proportional hazard assumption; there-
fore, the model was stratified for them solving the non-
proportional issues arising [25]. Age was implicitly adjusted
for in the model. Analyses were performed: (a) jointly for
confirmed and probable hospitalized rotavirus cases, and
(b) for confirmed hospitalized rotavirus cases only, evaluat-
ing also the effect of being partially or fully vaccinated. An
additional analysis on children fulfilling the product infor-
mation criteria for timing of vaccination was also carried
out (maximum age at administration of the 3rd dose for
RV5 was 32 weeks).
In another analysis, we estimated VE by annual rotavirus
epidemic season (December-April) among fully vaccinated
children. The models were adjusted for gender, receipt
of at least one vaccine in a private center, and zip code
(random effects).
All analyses were performed by vaccine brand. Analyses
were carried out using R Statistical Software (Foundationfor Statistical Computing, Vienna, Austria) version 3.0.3.
All tests were two-sided with a significance level of 0.05.
Ethical considerations
The Ethics Research Committee of the Dirección General
de Salud Pública/Centro Superior de Investigación en
Salud Pública approved the study.
Results
Characteristics of the study population
The study included 174,924 eligible children, representing
59% of the 294,716 total eligible children of compatible
age covered by the NHS (Figure 1). Among them, 78,281
children were vaccinated against rotavirus, contributing
173,973 person-years to the study, and 96,643 children
were in the comparison group, contributing 216,416
person-years. The median follow-up was 1,013 days, with
an interquartile range (IQR) of 540–1,094 days.
Almost all (96.7%) rotavirus vaccinees had also received
PCVs. The cohort of children vaccinated with any rotavirus
vaccine, and the comparison cohort (children vaccinated
with pneumococcal vaccine) were similar with respect
to gender, residence status, and performance of a rota-
virus detection test during gastroenteritis hospitalization.
Children included in the rotavirus cohort were more likely
to be vaccinated in private centers (14.4% vs. 10.9%;
p < 0.001) and slightly more likely to be covered by the
universal health system (95.3% vs. 93.7%; p < 0.001) than
children included in the non-rotavirus cohort. Differences
in birth year between groups were found, reflecting differ-
ences in the uptake of each vaccine after their respective
introduction in the Spanish market and in the start and
end of suspension of each vaccine’s distribution by Spanish
authorities. An apparent lower uptake of the vaccines in
2012 was due to the end of the study period in mid-2012
(Table 1).
Of 78,281 children included in the rotavirus-vaccinated
cohort, 24,723 (32%) were vaccinated with at least one
dose of RV1, and 53,558 (68%) received at least one dose
of RV5. A total of 21,119 (85%) and 34,865 (65%), respect-
ively, of RV1 and RV5 vaccinees, completed the two and
three-dose series. Of them, 19,751 (94%) and 30,066 (86%)
of RV1 and RV5 vaccinees were vaccinated within the
times indicated in the respective product information.
Among children partially vaccinated, 3,604 children
received one dose of RV1, and 10,130 and 8,563 two and
one dose of RV5, respectively (Table 2).
Rotavirus vaccine effectiveness
There were 22 probable or confirmed rotavirus hospi-
talizations among children fully vaccinated with RV1,
20 among children fully vaccinated with RV5, and 768
among non-rotavirus vaccinated children. Among cases
vaccinated with RV1 and RV5, 22 (100%) and 19 (95%),
More number of doses than recomemded
Figure 1 Study population.
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the respective product’s indication. Adjusted VE against
probable or confirmed rotavirus hospitalization was
86% (95% CI: 78-91%) for a full two-dose series of RV1,
and 88% (95% CI: 81-92%) for a full three-dose series of
RV5. Adjusted VE in children in full compliance withthe product indication for timing of vaccine administra-
tion was 85% (95% CI: 77-90%) for RV1 and 87% (95%
CI: 80-92%) for RV5.
There were six probable or confirmed rotavirus hospi-
talizations in children partially vaccinated with RV1, six
in children vaccinated with two doses of RV5, and nine
Table 1 Characteristics of study population
RV1 cohort RV5 cohort Any rotavirus vaccine (RV1 or RV5) Comparison cohort
n = 24,723 n = 53,558 n = 78,281 n = 96,643
Gender
Male 12,882 (52.1%) 27,599 (51.5%) 40,481 (51.7%) 50,155 (51.9%)
Female 11,841 (47.9%) 25,959 (48.5%) 37,800 (48.3%) 46,488 (48.1%)
Birth yeara
2007 3,805 (15.4%) 3,924 (7.3%) 7,729 (9.9%) 22,013 (22.8%)
2008 9,429 (38.1%) 10,092 (18.8%) 19,521 (24.9%) 16,449 (17.0%)
2009 10,759 (43.5%) 9,688 (18.1%) 20,447 (26.1%) 13,147 (13.6%)
2010 666 (2.7%) 7,476 (14.0%) 8,142 (10.4%) 25,551 (26.4%)
2011 62 (0.3%) 16,597 (31.0%) 16,659 (21.3%) 16,063 (16.6%)
2012 2 (0.01%) 5,781 (10.8%) 5,783 (7.4%) 3,420 (3.5%)
Residence status (as registered in SIP)
Resident 24,451 (99.9%) 53,255 (99.98%) 77,706 (99.97%) 95,643 (99.9%)
Long-stay 17 (0.1%) 11 (0.02%) 28 (0.03%) 49 (0.1%)
Covered by the universal health systemb
Yes 23,319 (95.3%) 50,748 (95.3%) 74,067 (95.3%) 89,633 (93.7%)
No 1,149 (4.7%) 2,518 (4.7%) 3,667 (4.7%) 6,059 (6.3%)
Any vaccination by a private provider
Yes 2,846 (11.5%) 8,426 (15.7%) 11,272 (14.4%) 10,501 (10.9%)
No 21,877 (88.5%) 45,132 (84.3%) 67,009 (85.6%) 86,142 (89.1%)
AGEc hospitalizationd
At least one admission 230 (0.9%) 332 (0.6%) 562 (0.7%) 1,522 (1.6%)
Rotavirus test performed
During any AGE hospitalizationd 183 (79.6 %) 267 (80.4 %) 450 (80.1%) 1,185 (77.9 %)
aNumber of children born each year. The study period ended in June 2012.
bAnswer NO refers to requested extension of the assistance, without resources/solidarity card, out-of-date accreditation, or non-accredited at the time of
data extraction.
cAcute gastroenteritis.
dDischarge diagnosis of intestinal infectious disease (ICD-9-CM codes 001–009).
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and adjusted assessments for all outcomes and vaccin-
ation status studied are shown in Table 3.
There were no differences in adjusted VE between the
four-rotavirus epidemic seasons studied (there were no
cases in the vaccinated group during the season 2007–
2008) among fully vaccinated children (Figure 2).
Discussion
In this large population-based observational study includ-
ing 78,281 children vaccinated with rotavirus vaccines and
96,643 children vaccinated with PCVs (and not with
rotavirus vaccines), RV1 and RV5 showed high and similar
effectiveness in preventing hospitalizations among young
children. Our VE estimates are comparable to those ob-
tained in other observational studies performed in coun-
tries in which rotavirus vaccines are included in the official
schedules [13,26-28]. Our results are also similar to those
obtained in post-licensure studies in countries withoutsystematic rotavirus vaccination, including Spain [11,29,30].
Nevertheless, our study design, large sample size, and long
study period, which included five rotavirus epidemic sea-
sons, gave us the opportunity for providing precise
adjusted effectiveness estimates by vaccine brand, in-
cluding in partially vaccinated children, across a large
time period.
Both vaccines were evaluated using a specific case def-
inition. Since a discharge code may represent a rule-out
diagnosis, an unconfirmed diagnosis, or may have been
recorded incorrectly, we previously assessed the positive
predictive value of the ICD-9-CM rotavirus code (008.61)
using as gold standard the microbiological results from
RedMIVA. The high positive predictive value found
(≅90%) showed that hospitalized cases with or without
a detection test result available could both be included, in-
creasing the total number of study cases while assuring
specificity in the case definition [31]. Accordingly, there
were no significant differences between VE estimates based
Table 2 Patterns of vaccine administration in the
rotavirus vaccinated cohort
Rotavirus vaccination RV1 RV5
First dose n = 24,723 n = 53,558
Week of age at vaccination
(median; IQR)
9 (9–11) 9 (9–10)
Dose administration >12 weeksa
(n; %)
5,263 (21%) 6,515(12%)
Second dose n = 21,119 n = 44,995
Week of age at vaccination
(median; IQR)
18 (17–19) 17 (15–18)
Dose administration >24 weeksb
(n; %)
1,172 (6%) -
1st - 2nd dose interval in weeks
(median; IQR)
9 (8–9) 8 (5–9)
1st - 2nd dose interval 22–27 days
(n; %)
213 (1%) 1,162 (3%)
Third dose - n = 34,865
Week of age at vaccination
(median; IQR)
- 26 (19–27)
Dose administration >32 weeksc
(n; %)
- 179 (1%)
2nd – 3rd dose interval in weeks
(median; IQR)
- 8 (5–9)
2nd – 3rd dose interval 22–27 days
(n; %)
- 1,338 (4%)
a>84 days; b>168 days; c>224 days.
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probable cases.
Natural immunity is acquired after early exposure to the
virus and confers protection against subsequent infections.
Although the protective effect of a natural infection is
variable [3,4], the fact that rotavirus vaccines are notTable 3 Unadjusted and adjusted rotavirus vaccine effectiven
gastroenteritis by vaccine brand and number of doses receiv
Confirmed and probable hospitalized rotaviru
Vaccination status Cases VE (95% CI), %
Unadjusted A
Fully vaccinated
RV1 22 87(81–92) 86
RV5 20 89(82–93) 88
RV1a 22 87(80–91) 85
RV5a 19 88(80–92) 87
Partially vaccinated
RV1 (1 dose) 6 84(65–93) 82
RV5 (2 doses) 6 90(77–95) 89
RV5 (1 dose) 9 83(68–91) 83
Unvaccinated
768 - -
aChildren fulfilling the product information criteria for timing of vaccination.funded by the public health system, and must therefore
be paid by parents, could have influenced the pediatrician’s
recommendation to vaccinate children who suffered a
prior rotavirus disease. By censoring children after the
first confirmed rotavirus infection, we may have de-
creased the potential risk of confounding by indication
[32]. Although we excluded children with prior known
rotavirus infections, we could not be certain that all
vaccinated children were naïve to rotavirus infections,
because: (1) asymptomatic infections could provide pro-
tection similar to that induced by symptomatic disease [3],
(2) our study began in 2007, year in which RedMIVA was
still being implemented and not all laboratory results were
available [22], and (3) an indeterminate number of ambu-
latory/Emergency Department cases were not tested for
rotavirus infection. Nevertheless, these issues could not
have substantially affected our results because the result-
ing bias should have driven results towards finding no dif-
ferences between the groups being compared, and our VE
estimates were high. Moreover, our results were com-
parable to those from other studies. Nonetheless, by cen-
soring after ‘non-hospitalized’ infections, we might have
introduced an informative censoring bias also affecting
our VE estimates (these children are unlikely to subse-
quently have a rotavirus hospitalization). Given these
concerns, we also performed an additional analysis with-
out censoring children with non-hospitalized cases, and
our VE estimates remained unchanged (results available in
authors’ response to reviewers).
The fact that these vaccines were not included in the
official immunization schedule might suggest the possibil-
ity of significant underreporting of vaccination, and differ-
ences between rotavirus vaccinees and non-vaccinees
with respect to risk factors for natural disease. For theseess in preventing hospitalizations due to rotavirus
ed
s cases Confirmed hospitalized rotavirus cases
Cases VE (95% CI), %
djusted Unadjusted Adjusted
(78–91) 20 86(78–91) 84(75–90)
(81–92) 12 91(85–95) 91(84–95)
(77–90) 20 85(77–91) 84(74–90)
(80–92) 11 91(84–95) 91(83–95)
(60–92) 3 90(69–97) 89(66–97)
(75–95) 5 89(74–96) 89(73–95)
(66–91) 7 84(65–92) 84(66–92)
616 - -
Figure 2 Adjusted rotavirus vaccine effectiveness in preventing hospitalizations due to rotavirus gastroenteritis (confirmed or probable
cases) among children fully vaccinated, by rotavirus season (1st December through 30th April), and by vaccine brand.
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children registered as having received another vaccine not
included in the official immunization schedule, which
should have minimized differences in the likelihood of
vaccination registration and in socioeconomic conditions
(a proxy for risk factors for disease and hospitalization).
Despite using pneumococcal conjugate vaccinees as the
comparison cohort, some residual socio-economical differ-
ences between groups could have remained because this
vaccine is provided free of charge to a small group of chil-
dren at high risk for complications of pneumococcal infec-
tion. The slight differences found between rotavirus and
non-rotavirus vaccinees for having received at least one
vaccine in a private center, and for having health cover-
age at the time of data extraction, could reflect in part
the presence of this small group. Nevertheless, the dif-
ferences found in VE between unadjusted and adjusted
analyses were minimal, which suggests that the effect of
confounding by socio-economical conditions, if any, was
small. Also, since rotavirus and PCV are not included in
the official immunization schedule, and are, therefore, ad-
ministered mostly in private practices, our estimates could
not be generalized to the overall Valencia population.
Nonetheless, although the benefits of vaccination may
be more important in higher risk groups, there is no bio-
logical reason to believe that the effectiveness of rotavirus
vaccines within the same geographic region should differ
by socio-economic conditions.
VE estimates were also high for partially vaccinated
children. These findings were similar to other observational
studies examining RV5 [28,33] and higher than those study-
ing RV1 [34]. Because the vaccine is not funded by the pub-
lic health system, there is a possibility of underreporting
of rotavirus vaccination by providers. Nonetheless, ac-
cording to a recent study, among all rotavirus vaccinedoses distributed in Valencia during 2009–2012, most
(86%) were registered in SIV as administered in children
aged <1 year [35]. However, we cannot rule-out the possi-
bility that some doses could have been missed or ad-
ministered in private vaccination centers not using SIV,
or outside the health care setting.
Another limitation might be due to the lack of system-
atic stool analyses among hospitalized children with acute
gastroenteritis. Nonetheless, no differences in the propor-
tions of laboratory tests performed were observed between
the two cohorts. Moreover, as indicated earlier, the PPV of
a hospital discharge diagnosis of rotavirus was high [31].Conclusions
In summary, RV1 and RV5 were over 85% effective in
preventing rotavirus hospitalizations among young chil-
dren living the Valencia Region, Spain, during the study
period. The high effectiveness shown should contribute
to decisions regarding the inclusion of rotavirus vaccines
in the official immunization schedule in Spain. Additional
information on rotavirus vaccine safety, duration of pro-
tection, and benefit-risk assessments in our setting will
also be needed to inform such deliberations. This study
also shows that Valencia’s databases could be used for the
assessment of the effectiveness of vaccines not included in
the official schedule.Abbreviations
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